NovaBay Pharmaceuticals, Inc.(AMEX & TSX: NBY, http://novabaypharma.com), a biopharmaceutical company developing products for the treatment or prevention of a wide range of bacterial and viral infections, will present at the 10th Annual BIO CEO and Investor Conference and the 20th Annual OC Growth Stock Conference.
The BIO CEO presentation will be held at the Waldorf-Astoria in New York City on Tuesday, February 12, 2008 at 12:30PM/EST. Members of the investment community, the media, and other interested parties can access a live audio webcast of NovaBay’s presentation by visiting the following hyperlink: BIO CEO NovaBay Webcast.
The 20th Annual Roth Capital Partners OC Growth Conference will be held at the Ritz-Carlton Laguna Niguel in Dana Point, California. NovaBay’s presentation is on Thursday, February 21, 2008 at 10AM/PST in the Ritz Ballroom Salon 6. Members of the investment community, the media, and other interested parties can access a live audio webcast of NovaBay’s presentation by visiting the following link: ROTH NovaBay Webcast
At each of the conferences, Ron Najafi, Ph.D., NovaBay’s Chairman and Chief Executive Officer, will provide an overview of the company’s clinical development programs and the status of its licensing agreements with its corporate partners, Alcon, Inc. (NYCE: ACL) and Kinetic Concepts, Inc. (NYSE:KCI). Dr. Najafi will also discuss NovaBay’s recent announcement that it has received clearance from the U.S. Food and Drug Administration to begin human clinical trials of its lead Aganocide® compound, NVC-422, a novel non-antibiotic anti-infective that has shown potent in vitro activity against major pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
About NovaBay Pharmaceuticals, Inc.
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative product candidates for the treatment or prevention of a wide range of infections in hospital and non-hospital environments. NovaBay has discovered and is developing a class of non-antibiotic anti-infective compounds, which it has named Aganocides, based upon small molecules generated by white blood cells that defend the body against invading pathogens. NovaBay believes that the Aganocide® compounds could form a platform on which to create a variety of products to address different needs in the prevention and treatment of bacterial, fungal and viral infections, including methicillin-resistant Staphylococcus aureus (MRSA). NovaBay has entered into a licensing and research collaboration agreement with an affiliate of Alcon, Inc. for use of the Aganocide® compounds in eye, ear and sinus infections and in contact lens solutions. In addition to its Aganocide® compounds, NovaBay is developing NVC-101, which it refers to as NeutroPhase, and has entered into a license agreement with an affiliate of Kinetic Concepts, Inc. for the use of NeutroPhase in wound care applications.
NovaBay recently received clearance from the US Food and Drug Administration of its Investigational Drug Application (IND) for NVC-422, the company’s lead Aganocide® compound, so that human clinical trials of NVC-422 in the prevention of catheter associated urinary tract infections (CAUTI) can begin. NVC-422 is a novel topical non-antibiotic anti-infective compound that has been shown to destroy pathogens extremely rapidly in vitro. NVC-422 is highly active against gram-positive and gram-negative bacteria, fungi and viruses in vitro, including drug-resistant strains such as MRSA (USA100 and USA300 strains), mupirocin-resistant and vancomycin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus (VRE). NVC-422 has been shown to be effective in vitro against the causative agents of urinary tract infections, including multidrug-resistant Escherichia coli and Pseudomonas aeruginosa. In addition to its potential use to prevent CAUTI, NVC-422 is in clinical development at NovaBay under the trademark AgaNase, to reduce the risk of surgical site infections and to reduce the risk of MRSA infections in hospital environments. Formulations of NVC-422 are in advanced pre-clinical development at Alcon, Inc. for use against ophthalmic and ear infections. NVC-422 is not an antibiotic and the company believes it is unlikely to contribute to antibiotic resistance.
NovaBay™, AgaNase™, Aganocide® and NeutroPhase™ are trademarks of NovaBay Pharmaceuticals, Inc. All other trademarks and trade names are the property of their respective owners.
For more information visit the company’s website at: www.novabaypharma.com
This release contains forward-looking statements, which are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding the development and potential benefits of, and the market opportunities for, NovaBay’s product candidates. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in discovery, development, testing, regulatory approval, production and marketing of the company’s product candidates, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company’s intellectual property or trade secrets, the company’s ability to obtain additional financing as necessary and unanticipated research and development and other costs. The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
The Investor Relations Group
Adam Holdsworth / Rachel Colgate / Erica Ruderman
Janet Vasquez / Laura Colontrelle